DFF332 Elicits Efficacy and Is Safe in Advanced Clear Cell RCC

The small molecule inhibitor DFF332 elicited clinical activity and had a tolerable safety profile in patients with advanced clear cell renal cell carcinoma.

Related Keywords

California ,United States ,Sumanta Kumar Pal ,Bladder Cancer Disease Team ,Kidney Cancer Program ,Database Consortium ,International Metastatic ,Medical Oncology ,Therapeutics Research ,Hope Comprehensive Cancer Center ,